Lymphoma Clinical Trials

85 studies are recruiting for lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

   The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with soma…

   Stage

   Phase 1

   Ages

   2 to 18

   Site

   UCSF Benioff Children's Hospital, San Francisco, California

   Locations

   6 in total

   Run by

   ITM Solucin GmbH

   See if you can join NCT06441331 on ClinicalTrials.gov

2. Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

   Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and le…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03223610 on ClinicalTrials.gov

3. Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

   Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other treatments. Objectives: To see if Nivolumab slows the growth of …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03258567 on ClinicalTrials.gov

4. AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

   This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Research Site, Duarte, California

   Locations

   39 in total

   Run by

   AstraZeneca

   See if you can join NCT06137144 on ClinicalTrials.gov

5. Sample Collection and Tracking for the Developmental Therapeutics Clinic

   Background: People who join a study in the Developmental Therapeutics Clinic (DTC) have tests. These include blood draws and biopsies. Researchers collect data from these samples. Some people take part in more than one study at the DTC. At this time, data are connected only with one single study. R…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03269578 on ClinicalTrials.gov

6. A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

   The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Saddleback Memorial Medical Center, Laguna Hills, California

   Locations

   18 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06624085 on ClinicalTrials.gov

7. A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

   Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor k…

   Stage

   Phase 1

   Ages

   Up to 25

   Site

   Children's Hospital Los Angeles, Los Angeles, California

   Locations

   68 in total

   Run by

   Turning Point Therapeutics, Inc.

   See if you can join NCT04094610 on ClinicalTrials.gov

8. TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

   The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stanford Medicine Cancer Center, Palo Alto, California

   Locations

   14 in total

   Run by

   Treeline Biosciences, Inc.

   See if you can join NCT07082803 on ClinicalTrials.gov

9. A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

   The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope Cancer Center, Duarte, California

   Locations

   82 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06084936 on ClinicalTrials.gov

10. A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

    The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.

    Stage

    Phase 2

    Ages

    0 to 17

    Site

    University Hospitals Cleveland Medical Center, Cleveland, Ohio

    Locations

    5 in total

    Run by

    Spectrum Pharmaceuticals, Inc

    See if you can join NCT04570423 on ClinicalTrials.gov

11. A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

    The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University Of Colorado, Aurora, Colorado

    Locations

    40 in total

    Run by

    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT07015242 on ClinicalTrials.gov

12. Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

    Background: - Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: - To o…

    Stage

    Not phased

    Ages

    3 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT01441089 on ClinicalTrials.gov

13. Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

    Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically in…

    Stage

    Not phased

    Ages

    5 and older

    Site

    Children s Hospital of Los Angeles, Los Angeles, California

    Locations

    3 in total

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT05237986 on ClinicalTrials.gov

14. Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

    Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Age is a risk factor for Alzheimer's…

    Stage

    Not phased

    Ages

    19 and older

    Site

    University of Nebraska Medical Center, Omaha, Nebraska

    Run by

    University of Nebraska

    See if you can join NCT04898790 on ClinicalTrials.gov

15. Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

    To find out if adding treatment with fecal microbiota transplantation (FMT) is effective at treating gut-related side effects of antibiotic treatment in participants who are receiving standard therapy with anti-CD19 chimeric antigen receptor T-cell (CAR-T cell) therapy.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06218602 on ClinicalTrials.gov

16. DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics

    The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and providers, improves patient-reported values-concordance of initial treatm…

    Stage

    Not phased

    Ages

    60 and older

    Site

    Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06296368 on ClinicalTrials.gov

17. Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

    This is an open-label, single institution, Phase 1 study of Venetoclax, Dexamethasone, Bortezomib, and Daratumumab for adolescent and young adult participants with relapsed or refractory T-ALL or T-LBL

    Stage

    Phase 1

    Ages

    12 to 30

    Site

    UT MD Anderson, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07513129 on ClinicalTrials.gov

18. Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors

    The goal of this clinical trial is to learn if a mind body resilience group program can help increase lymphoma survivors' ability to cope with and manage the challenges that come with the transition into early post treatment survivorship.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mass General Brigham, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT07014293 on ClinicalTrials.gov

19. A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

    The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Georgetown University (Data Collection Only), Washington D.C., District of Columbia

    Locations

    9 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05389293 on ClinicalTrials.gov

20. Vaccine Responses in Patients With B Cell Malignancies

    Background: People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers …

    Stage

    Phase 4

    Ages

    18 to 90

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Heart, Lung, and Blood Institute (NHLBI)

    See if you can join NCT05170399 on ClinicalTrials.gov

21. Mosaic Trial for Stem Cell Transplant Recipients

    The goal of this clinical trial is to learn if using an intervention website (Mosaic) improves selected patient-reported outcomes in adult blood cancer patients undergoing allogeneic or autologous stem cell transplant, compared to using an educational website (control group). Patients will be recru…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Georgetown University School of Medicine, Washington D.C., District of Columbia

    Locations

    3 in total

    Run by

    Northwestern University

    See if you can join NCT06960993 on ClinicalTrials.gov

22. Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

    This is a pilot clinical trial determining the effect of a Methionine-reduced diet on serum levels in subjects with solid tumors. These are subjects who will receive systemic standard of care cancer therapy.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT07628634 on ClinicalTrials.gov

23. Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy

    Higher gut microbiome diversity has been associated with improved survival following autologous stem cell transplantation in multiple myeloma and lymphoma. This study hypothesises that prebiotic supplementation with resistant starch (RS) will improve gut microbiome diversity at time of stem cell en…

    Stage

    Not phased

    Ages

    19 and older

    Site

    Unversity of Nebraska Medical Center, Omaha, Nebraska

    Run by

    University of Nebraska

    See if you can join NCT05135351 on ClinicalTrials.gov

24. The CARDIOPROTECT Trial

    This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care R-CHOP or pola-R-CHP treatment regiments. The names of the study drugs inv…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Run by

    Beth Israel Deaconess Medical Center

    See if you can join NCT07654426 on ClinicalTrials.gov

25. A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

    To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06563505 on ClinicalTrials.gov